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Hepatitis C virus (HCV) infects over 170 million people in the world. While a minority
of individuals are able to naturally clear this hepatotropic virus using their immune
system, most people go on to develop a lifetime chronic infection that can result in
severe liver pathology, potentially leading to liver cirrhosis and hepatic cellular carcinoma.
Investigations into acute immune responses and spontaneous clearance of the virus
are severely hampered by difficulties in identification of relevant patient cohorts. While
the role for the adaptive immune response in viral clearance is well established, it is
becoming clear that the innate immune system also impacts on HCV outcome. The
innate immune response to infection is likely to influence the type of adaptive immune
response that develops and will ultimately influence if the virus is cleared or develops
into a chronic infection. Natural Killer (NK) cells are lymphocytes that have important
anti-viral functions including direct cytotoxicity of infected cells and the production of
inflammatory cytokines, e.g., IFN-γ. They are generally considered to be cells of the
innate immune system, although there is increasing evidence that NK cells adapt and
persist in response to particular viral infections. NK cells are altered in patients with acute
and chronic HCV infection. There is increasing evidence from both cellular and genetic
studies that NK cells modulate HCV outcome. This review will describe and discuss the
current experimental and clinical evidence of a role for NK cells in HCV infection and
describe recent discoveries that are likely to play a role in future research.
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Introduction
Hepatitis C virus (HCV) infects approximately 170 million people in the world (Alter and Seeff,
2000). HCV infects hepatocytes and while virus can be cleared by the immune system in a minority
of individuals, most people develop a chronic lifetime infection associated with progressive liver
disease (Shepard et al., 2005; Micallef et al., 2006; Rehermann, 2009). It is not yet clear why
some individuals can spontaneously clear infection while others cannot, and both viral and host
factors are likely to impact on this. Most research has focussed on the development of adaptive
immunity in this context (Cooper et al., 1999; Lechner et al., 2000; Thimme et al., 2002). However,
there is substantial evidence emerging to suggest that the innate immune system also significantly
contributes to HCV outcome (Ge et al., 2009; Rehermann, 2009; Suppiah et al., 2009; Tanaka et al.,
2009; Nattermann, 2011; Prokunina-Olsson et al., 2013). In addition to cells of the innate immune
Gardiner NK cells in HCV
system, including Natural Killer (NK) cells, the focus on this
review, cytokines such as the type 3 IFN family strongly impact
on HCV outcome (Thomas et al., 2009; Tillmann et al., 2010;
Dring et al., 2011), although the mechanisms involved remain
elusive.
The treatment for HCV has historically been a combination
of IFNα and ribavirin but this is changing with the advent of
direct acting antivirals (DAAs) (Zeuzem et al., 2011, 2014; Afdhal
et al., 2014). DAAs have revolutionized treatment of HCV and
IFNα free therapy is currently being introduced. While further
refinements of these drugs are likely, the DAAs are not without
their problems. Currently, their cost is hugely expensive although
this should come down in the future. At present, DAA therapy
is only a viable option for developed countries. Furthermore,
identification of DAA resistant variants of HCV have already
been identified (Carganico et al., 2014; Hedskog et al., 2015; Ji
et al., 2015). There are also likely to be complications in terms of
drug interactions in particular patient subsets, e.g., patients co-
infected with HIV-1 (Burgess et al., 2015; Soriano et al., 2015) and
reinfection is likely to occur in high risk patients (Baumert et al.,
2014). Therefore, alternative therapeutic approaches, including
development of a prophylactic vaccine, remain important goals
and understanding the immune response during HCV infection
is key to ensure appropriate development of protective immunity
(Baumert et al., 2014). Modulation of innate immunity, including
NK cells, provides one potential mechanism for improving
immunity to vaccination.
NK cells are lymphocytes that have traditionally been classified
by Immunologists as part of the innate immune response as
they can mediate rapid effector responses and do not necessarily
need prior sensitization for effector functions such as cytotoxicity
(Caligiuri, 2008). This view point is changing rapidly however
with the demonstration of long lived, activated NK cells that
have sustained functions beyond the classical “innate” time-frame
(Cooper et al., 2009; Sun et al., 2009; Björkström et al., 2011).
NK cells are best known for their anti-viral activities and anti-
tumor activities. They can kill virally infected cells and produce
IFNγ cytokine that has direct anti-viral functions in addition
to modulating the adaptive immune response (Caligiuri, 2008;
Wang et al., 2008). NK cells have been shown to kill HCV infected
hepatocytes (Larkin et al., 2006; Stegmann et al., 2010). Indeed,
there is substantial evidence accumulating to support that they
play an important role in HCV infection and although they may
be important during the immune response to acute infection,
they may continue to play significant roles during chronic HCV
infection and during treatment. Indeed, it is possible that NK
cells, rather than being just a friendly force, may contribute to
development of chronic infection or indeed immune mediated
pathology associated with chronic infection.
This review summarizes the current studies, both genetic and
cellular, that provide evidence of a role for NK cells during acute
and chronic HCV infection. In addition, significant advances
have been made in recent years in terms of understanding
NK cell biology including an appreciation for the impact of
cytomegalovirus (CMV) on NK cell responses, the discovery of
tissue resident NK (trNK) cells and a growing awareness that
NK cells may play previously unanticipated roles during the
adaptive immune response, possibly even contributing to disease
pathology. These all remain to be explored in terms of their
impact during HCV infection and will be discussed inmore detail
later.
Hepatitis C is a human disease. HCV does not infect rodents
and although progress has been made, no robust small animal
models for the study of the immune response to HCV exist
(Vercauteren et al., 2014). In vitro culture systems for HCV
have been developed and while they are not very physiological,
they allow dissection of particular aspects of HCV infection
(Lohmann and Bartenschlager, 2014). Therefore, most studies on
the role of the immune system in HCV use human cohorts and
samples for analysis. HCV infects hepatocytes and it is likely that
most relevant immunology occurs locally in the liver. In the case
of NK cells, this is probably particularly pertinent as NK cells
are particularly enriched in the liver accounting for over 30%
of lymphocytes compared to a frequency of approximately 10%
of peripheral blood lymphocytes in humans (Hata et al., 1990;
Satoh et al., 1996; Norris et al., 1999; Doherty and O’Farrelly,
2000). While liver samples from patients with chronic HCV are
relatively easier to come by, it is substantially more difficult to
get liver samples from healthy controls, and our knowledge of
events in the liver is relatively poor compared to information
on systemic immune events during HCV infection. The limited
data available suggest that differences exist between matched
peripheral blood and hepatic NK cells in terms of phenotype
and function, and that differences are also seen between hepatic
NK cells of patients with chronic HCV compared with controls
(Kawarabayashi et al., 2000; Varchetta et al., 2012). Despite this
caveat, there are clear changes in systemic immune cells during
infection and there is some evidence that changes observed in the
periphery are similar to those seen in liver albeit with relatively
lower levels of magnitude (Ahlenstiel et al., 2010).
Genetic Analysis of KIR Genes Provides
Evidence of a Role for NK Cells Role in
HCV
Evidence of a role for NK cells in HCV comes from
several different sources, including genetic and cellular settings.
Identifying the contribution of the immune system, including
NK cells, to either resolution of infection or the development of
chronic HCV infection is not a trivial task given the difficulties
in identifying appropriate control cohorts. Many individuals that
spontaneously resolve HCV infection are often not aware of
their infection and identification of such individuals is extremely
difficult (Micallef et al., 2006; Cox et al., 2009). Approaches
for comparison of spontaneous resolution vs. development
of chronic infection have therefore included retrospective
genetic analysis of iatrogenic cohorts of patients given HCV
contaminated blood products and prospective analysis of high
risk patient groups, e.g., intra-venous drug users (IVDU). Other
studies have used a variety of control groups, e.g., healthy normal
donors or non-infected IVDU patients to compare to chronic
infection but this analysis is confounded by the fact that within
the control group, some of the individuals would resolve and
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others would develop chronic infection if infected with HCV.
Heterogeneity of cohorts including ethnicity, genotype of virus,
route of infection, and presence of other co-morbidities all
complicate analysis as they can contribute to HCV outcome
(Thimme et al., 2002; Shepard et al., 2005). Thus, each studymust
be examined on its own merits in terms of appropriate controls
and samples numbers.
One of the biggest breakthroughs in NK cell biology was the
discovery of a family of germ line encoded receptors that are
expressed almost exclusively by NK cells and that are key to
NK cell recognition and function (Vilches and Parham, 2002).
Thirteen highly polymorphic Killer cell immunoglobulin-like
receptors (KIR) genes reside on chromosome 19 in the Leukocyte
Receptor Complex. Some of the genes encode inhibitory
receptors and other appear to encode activating receptors,
although their biology is less well understood (see Figure 1).
KIR receptors recognize conserved epitopes on HLA class I
molecules. In its simplest form, a dimorphism at residues 77xx80
of the HLA-C heavy chain encodes either HLA-C1 or HLA-C2
epitopes that are recognized by KIR2DL3 (including KIR2DL2
variants) and KIR2DL1 respectively (Vilches and Parham, 2002).
Furthermore, this same region of the HLA-B heavy chain encodes
the Bw4 epitope that provides a ligand for KIR3DL1 receptor.
Thus, HLA-C1, HLA-C2, and HLA-Bw4 are the three HLA class
I ligands that are recognized by KIR. However, KIR recognition
of HLA is more complex than this as KIR2DL2/3 receptors have
some cross-reactivity with HLA-C2 alleles (Moesta et al., 2008).
Furthermore, although it will not be discussed in this review,
there is also evidence that KIR recognition is influenced by
peptide presented by HLA class I molecules and that this can alter
NK cell recognition and function (Rajagopalan and Long, 1997;
Cassidy et al., 2014).
Our knowledge of basic KIR biology (expression, specificity,
function) lags well behind the advances we have made in terms of
KIR genetics. This is partly due to the difficulties in developing
specific reagents for proteins with a high degree of similarity
(Gardiner, 2008). However, the number of KIR genes, the high
degree of functional polymorphism of these genes, e.g., impact of
KIR3DL1 allelic variation on HLA-Bw4 recognition (O’Connor
et al., 2007), the existence of complimentary receptor systems
(CD94/NKG2), the polygenic and polymorphic nature of HLA-
class I ligands and the lack of KIR in the mouse make functional
cell biology experiments challenging.
Despite this, analysis of KIR genes is relatively straightforward
although the number of KIR genes, and the common requirement
to also study HLA class I (given the epistatic nature of functional
interactions), mean that large cohorts are required for studies to
have adequate statistical power. In terms of HCV research, many
studies have investigated a role for KIR genes and their ligands
in infection outcome or treatment response. In terms of evidence
FIGURE 1 | Killer cell immunoglobulin-like receptors (KIR). Killer cell immunoglobulin-like receptors (KIR) are encoded for by genes found in the leukocyte
receptor complex on chromosome 19. KIR have either 2 or 3 Ig extracellular domains. KIR can have either long or short cytoplasmic tails. The long cytoplasmic tails
contain immune-tyrosine based inhibitory motifs (ITIMs) that transduce inhibitory signals to the NK cell upon recognition of HLA class I ligand. KIR with short
cytoplasmic tails lack intrinsic signaling capabilities. However, they have a charged residue in their transmembrane domain that allows interaction with an adaptor
protein (DAP12) that transduces activating signals to NK cells through Immunotyrosine based activatory motifs (ITAMs). Some HLA class I ligands are recognized by
activating KIR but for most short-tailed KIR, the ligands are unknown. KIR recognize conserved epitopes of HLA class I receptors. KIR3DL2 recognize specific HLA-A
alleles (HLA-A3/A11) and are sensitive to the peptide present in the antigen binding groove. KIR3DL1 recognizes the HLA-Bw4 serological epitope present in some
HLA-B and HLA-A alleles (encoded by residues 77–83 of α1 domain of the HLA class I heavy chain). KIR2DL1 and KIR2DL2/3 recognize HLA-C allotypes. Specificity
is determined by a dimorphism at 77xx80 of the HLA class I heavy chain. KIR2DL1 recognizes HLA-C2 epitope while KIR2DL2/3 recognize the HLA-C1 epitope.
KIR2DS1 recognizes HLA-C2 and KIR2DS2 recognizes HLA-C1; 2DS4; KIR3DS1 has recently been described to recognize B*57:01 in a peptide specific manner.
Some non-HLA encoded ligands for activating KIR have been identified, e.g., viral haemagglutinin but for many, no physiological ligands have yet been defined.
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that NK cell genes contribute to either spontaneous resolution
or chronic infection, particular combinations of KIR and HLA
have been identified that impact HCV infection outcome. One of
the first large studies identified that KIR2DL3, when present on
a homozygous ligand background (HLA-C1/C1), was associated
with spontaneous resolution of HCV infection (Khakoo et al.,
2004). This cohort was very heterogeneous but had large sample
numbers (n = 1037). The authors hypothesized that as
KIR2DL3 binds HLA-C1 with a weaker affinity (compared with
KIR2DL2 binding of HLA-C1), it would be easier to overcome
this inhibitory interaction; therefore, NK cells in individuals
with this combination of receptor and ligand would be more
easily activated during HCV infection resulting in a better
outcome. When stratified into patients infected by transfusion
(predicted higher dose of HCV) or non-transfusion (e.g., needle-
stick injuries with predicted lower dose of HCV exposure), the
beneficial effect of KIR2DL3/HLA-C1/C1 was only seen with
the non-transfusion group, suggesting that NK cells may make
a more effective contribution to the immune response when
there is a more limited exposure to virus. The relevance of this
KIR2DL3/HLA-C1/C1 genotype has been supported as beneficial
in acute HCV infection by the same group (Knapp et al., 2010)
and a higher frequency of 2DL3 expressing NK cells has been
observed in a cohort of exposed uninfected individuals (Thoens
et al., 2014); however, other studies, albeit with different cohorts,
have not observed this association (Montes-Cano et al., 2005;
Rauch et al., 2007; Thoens et al., 2014).
We have previously published on the contribution of KIR
genes to HCV outcome in the Irish anti-D cohort (Dring et al.,
2011). These patients were infected by HCV contaminated anti-
D immunoglobulin in 1977/79. As the cohort were infected
from a single source, they provide a rare opportunity to look at
the impact of the host immune response in HCV outcome in
the absence of confounding variables, e.g., virus heterogeneity.
In this group, we found a trend toward KIR2DL3/HLA-C1
contributing to resolution of HCV infection as the frequency
of KIR2DL3+/HLA-C1/-C1 was higher in patients that resolved
(n = 247) compared to those that developed chronic infection
(n = 296). However, the Khakoo model predicts that this
effect should be stronger on aKIR/HLA homozygous background
but we did not find this in our cohort (Khakoo et al., 2004).
One possible explanation for this difference might be due
to differences in the route of viral transmission. Our cohort
is more similar to the patients that were infected through
blood transfusion products for whom no beneficial effect of
KIR2DL3/HLA-C1 was observed. Although our data did not
reach statistical significance, they suggested that NK cells could
potentially contribute to resolution of HCV infection through
KIR2DL3/HLA-C1, even when patients are initially exposed to
higher levels of HCV.
We also identified KIR B haplotype associated gene, KIR2DS3,
as a risk factor in the Irish anti-D cohort for development of
chronic HCV infection when present with HLA-C2 (Dring et al.,
2011). This relevance of this finding was subsequently confirmed
when it was shown to also be associated with HCV treatment
failure in an Irish cohort of HCV/HIV-1 co-infected patients
(Keane et al., 2013). We do not yet understand the mechanism
for the association observed as KIR2DS3 is not expressed at
the cell surface (VandenBussche et al., 2009) and there is no
ligand identified for KIR2DS3 (Moesta et al., 2010). However,
the HLA-C2 association makes it likely that a KIR gene in
linkage disequilibriumwithKIR2DS3 could be responsible for the
biological effect. Given that KIR2DS3 was found in a haplotype
with KIR2DL1 and KIR2DL2 and these can both bind HLA-C2,
they are good candidate genes for the phenotype observed.
Another important point is that gene level analysis of KIR is
only informative up to a point. In our cohort, KIR2DL1 was
present in almost all donors and therefore was not informative as
a marker of clinical outcome. We know that KIR allelic variation
can affect NK cell function and it is likely that particular allotypes
are responsible for particular phenotypes. Given that we saw no
association with outcome for KIR2DL2 in our study, it is more
likely that a particular allele of KIR2DL1, in combination with
its HLA-C2 encoded ligand, may be detrimental in HCV in our
cohort.
It is also worth remembering that phenotypes are a result
of the net sum of interactions between KIR and HLA and that
allele level haplotypes rather than individual genes may be more
relevant in these situations. Also, the KIR/HLA system is only one
of the receptor ligand interactions thatmodulate NK cell function
and thus, effects observed are likely to be subtle. Finally, there
is a lot of genetic variability within KIR genes and haplotypes
and between different ethnic and geographical populations.
For example, there are two main KIR haplotypes described in
human populations. The KIR A haplotype is characterized by
predominantly inhibitory KIR that bindHLA class I ligands while
the KIR B haplotype containsmore diverse genes including short-
tailed KIR that are potentially encode activating receptors and
for many of whom, their ligands remain undefined. Populations
vary in the relatively frequencies of these haplotypes; the Japanese
and Australian aboriginals are at extremes with high KIR A
and B haplotypes respectively (Gonzalez-Galarza et al., 2011;
Parham et al., 2012). It is likely that genetic associations with
disease discovered may not be relevant in all global populations.
However, such genetic studies are essential for simplifying
some of the complexities and defining experiments to test the
molecular basis for the observations.
NK Cells are Activated in Acute HCV but
this does not Appear to Correlate with
Outcome
Genetics studies, although informative, are generally limited
to retrospective analysis and do not provide insights into the
immune events that occur immediately after infection and
that ultimately affect outcome. However, prospective studies
on acute HCV are hampered due to difficulties identifying
patients that have acute HCV infection and these studies
generally have low patient numbers. This caveat also precludes
analysis of multigenic complex gene families such as the
KIR, and prospective studies mainly focus on NK cell subsets
and expression of key activating and inhibiting receptors.
Unfortunately, conflicting reports abound with respect to almost
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all aspects of NK cell function and phenotype during acute
HCV infection and general conclusions discussed below must be
considered in this context.
In general, there is agreement that the frequency of NK
cells present does not correlate with resolution of infection
or development of chronic HCV infection (Alter et al., 2011;
Golden-Mason et al., 2014; Kokordelis et al., 2014). There is
also general agreement that there is a relative expansion of
CD56bright subset of NK cells during acute HCV infection with
a concomitant decrease observed in CD56dim subset of cells
(Morishima et al., 2006; Golden-Mason et al., 2008; Alter et al.,
2011). These subsets are characterized by different functions. The
CD56bright NK cells (KIR negative) are potent producers of IFNγ
and less cytotoxic than their CD56dim counterparts (Baume et al.,
1992; Fehniger et al., 1999; Jacobs et al., 2001). Some reports
find that NK cells are activated during acute HCV infection as
evidenced by changes in NK cell phenotype including expression
of activation receptors, e.g., NKG2D (Amadei et al., 2010;
Kokordelis et al., 2014) although expression of other receptors
associated with NK cell activation, e.g., NKp44 do not change
(Pelletier et al., 2010; Alter et al., 2011; Golden-Mason et al.,
2014). Most reports suggest that cytotoxic functions (TRAIL and
CD107a degranulation assays) of NK cells are increased during
acute infection (Amadei et al., 2010; Pelletier et al., 2010; Alter
et al., 2011; Werner et al., 2013; Golden-Mason et al., 2014).
However, there is no evidence to suggest that NK cell killing
potential during acute infection directly affects HCV outcome
(Amadei et al., 2010). Similarly, although the data are again
conflicted (Pelletier et al., 2010), there is a general consensus
that NK cells are activated to produce more IFNγ during acute
infection (Amadei et al., 2010; Werner et al., 2013; Kokordelis
et al., 2014), but this does not appear to impact on disease
outcome (Amadei et al., 2010).
The reality is that we do not yet understand the role that NK
cells play in the early immune response to HCV and not even
which effector functions are likely to be more important. Some
evidence suggests that IFN-γ might be key in inhibiting viral
replication (Thimme et al., 2002; Wang et al., 2008; Kokordelis
et al., 2014) while other data, showing that NK cell degranulation
potential during acute infection correlates with development of
a robust CTL response, supports NK cell cytotoxic functions
as a more important effector mechanism (Pelletier et al., 2010;
Werner et al., 2013). In addition to their roles as effector cells, NK
cells also modulate the development of adaptive immunity. This
is important for our understanding of how an adaptive immune
response develops but also in terms of potentially targeting NK
cells during HCV vaccination to improve protective immunity
generated. More basic research defining the role of NK cell
effector and regulatory functions in the immune response to
HCV is required (Golden-Mason et al., 2014).
NK Cells Have Altered Phenotype and
Function in Chronic HCV Infection
Most studies on the role of NK cells in HCV infection have
focussed on chronic infection (as patient samples are readily
available) and thus we have more data available about this aspect
of infection compared to any other. It is worth remembering
that by the time chronic infection is established, the immune
system has had an opportunity to clear the virus and has failed
to do so. By studying the immune systems of patients with
chronic infection, we aim to understand aspects of the immune
system that contribute to the development of chronic infection.
However, the nature of a chronic infection means that there
will be continued production of HCV virus particles over the
lifetime of the host. Thus, the environment in which the immune
system finds itself will be different. Prolonged presence of the
virus can impact of the immune system, e.g., induction of
immune evasion mechanisms (Herzer et al., 2003; Séne et al.,
2010; Park and Rehermann, 2014) but also, continuous and
chronic activation of immune cells can lead to altered functions,
including their becoming “exhausted” or anergic (Park and
Rehermann, 2014). Thus, it can be difficult to dissect cause
vs. effect, e.g., does an altered immune function in patients
predispose to the development of chronic infection or is it caused
as a result of chronic virus infection? Furthermore, it is likely that
dysregulated immune activities can also contribute to later onset
pathology associated with chronic viral infection, e.g., fibrosis.
Therefore, analysis of NK cells during chronic infection needs to
be considered against this background.
There is consistency across a number of studies to suggest
that although the overall frequency of NK cells is either
unchanged (or low) during chronic infection (Morishima et al.,
2006; Golden-Mason et al., 2008; Alter et al., 2011), there is a
relative dysregulation of NK cell subsets, with a decrease in the
CD56dim cells and conversely, an increase in the frequency of
CD56bright cells in the peripheral blood of patients compared
to healthy normal controls (Morishima et al., 2006; Golden-
Mason et al., 2008; Alter et al., 2011). Although these NK
cell subsets are ascribed general, albeit simplistic, functional
activities, e.g., CD56bright cells are generally considered more
potent at producing IFNγ, in reality, the functions of these
subsets become more blurred. For example, as CD56dim cells
account for approximately 90% of NK cells, they can be a
relatively major source of IFNγ when activated (Anfossi et al.,
2006; Horowitz et al., 2010). Indeed, there is evidence to support
that CD56dim cells can be a potent source of rapid IFNγ
production, prior to production by CD56bright cells (De Maria
et al., 2011).
In terms of alterations in receptor expression, there are few
consistent findings. Expression of natural cytotoxicity receptors
(NCR; NKp30, NKp44, and NKp46) or NKG2D, as activating
receptors, are reported as either up, down or not changing on
peripheral blood NK cells depending on the study (De Maria
et al., 2007; Ahlenstiel et al., 2010; Pelletier et al., 2010; Alter
et al., 2011). There is so much heterogeneity in terms of cohorts
in terms of both patient characteristics and viral factors that it is
difficult to find studies that are directly comparable and which
validate findings in a particular context.
One receptor that appears to be consistently upregulated in
patients with chronic HCV is NKG2A (Jinushi et al., 2004;
Alter et al., 2011; Golden-Mason et al., 2014). NKG2A forms
a heterodimer with CD94 on NK cells. It recognizes HLA-E
Frontiers in Microbiology | www.frontiersin.org 5 September 2015 | Volume 6 | Article 1061
Gardiner NK cells in HCV
molecules on target cells and inhibits NK cell function (Braud
et al., 1998; Lee et al., 1998). During chronic HCV infection,
intrahepatic HLA-E expression is increased. This is due in part
to binding of a HCV derived peptide that stabilizes expression at
the cell surface; this also facilitates inhibition of NK cell function
(Nattermann et al., 2005).
Given that cytotoxicity and cytokine production are two
key functions that are important in the NK cell response to
viral infection, these are been assessed in many studies. Along
with the heterogeneity of cohorts mentioned above, there is
also variability in the literature in terms of how experiments
are done, controls groups used, subsets of cells are analyzed,
how analysis is performed, e.g., frequency of expression (%)
vs. level of expression (mfi) and how the data are presented.
While there are occasional reports of unchanged (De Maria et al.,
2007) or even higher production (Golden-Mason et al., 2008),
there is a growing consensus, across a range of experimental
platforms, that peripheral blood NK cells from patients with
chronic HCV infection make less IFNγ than healthy normal
individuals (Jinushi et al., 2004; Oliviero et al., 2009; Ahlenstiel
et al., 2010; Alter et al., 2011).
The cytotoxic functions of NK cells appear to be transiently
increased during acute HCV viral infection (Amadei et al., 2010;
Pelletier et al., 2010; Werner et al., 2013). However, many studies
have confirmed that NK cell cytotoxicity is not impaired during
chronic HCV infection (Morishima et al., 2006; Golden-Mason
et al., 2008; Ahlenstiel et al., 2010; Alter et al., 2011). These
general observations are supported by one particular study that
stratified patients with chronic HCV on the basis of ALT levels
(Ahlenstiel et al., 2010). Patients with normal ALT levels had
normal NK cell activity while those with higher ALT levels,
associated with active infection, had higher cytotoxicity against
target cells. Overall, these data suggest that if NK cell cytotoxic
functions are important for viral clearance early after infection,
they are no longer an effective mechanism for viral clearance
once infection has become established. One consideration with
most of the cell function studies cited is that non-hepatic target
cells have generally been used and occasionally, differences have
been observed in terms of NK cell responses between common
haematopoietic target cells, e.g., K562, 721.221 and hepatic target
cells (Jinushi et al., 2004). Confirmation of these findings by
several laboratories, e.g., using the HCV replicon system would
be a worthy endeavor.
Upon recognition of a target cell, NK cells primarily kill
using molecules contained in their cytotoxic granules (measured
in the CD107a assay). However, they can also kill by receptor
mediated ligation using TRAIL, fas-ligand and membrane bound
lymphotoxin, to trigger apoptosis in target cells. Of these,
TRAIL expression has been reported to play a role in NK
cell recognition of HCV infected cells (Ahlenstiel et al., 2010;
Stegmann et al., 2010). In general, a modest upregulation of
TRAIL is reported during acute infection (Werner et al., 2013;
Golden-Mason et al., 2014) and it appears to remain elevated
during chronic infection. TRAIL receptors are also upregulated
onHCV infected hepatocytes (Jang et al., 2014). Increased TRAIL
expression on NK cells has also been associated with an ability to
induce apoptosis of hepatitis stellate cells and potentially inhibit
HCV associated development of fibrosis (Glässner et al., 2012).
However, it has also been reported that TRAIL is decreased
on hepatic NK cells of HCV infected individuals compared to
controls (Varchetta et al., 2012). Thus, it is not yet clear the role
that TRAIL plays in the NK cell immune response during HCV
infection.
In addition to these direct effector functions, NK cells can
regulate the development of adaptive immunity by a variety of
mechanisms, including interacting with Dendritic cells (DC).
There is a reciprocal interaction between NK cells and DC, and
activated NK cells have the potential to kill immature Dendritic
Cells (iDC), thereby limiting the strength of the downstream
adaptive immune response (Ferlazzo and Moretta, 2014). It has
been shown in a co-culture system with hepatic cells, that NK
cells from patients with chronic HCV infection had a reduced
ability to activate DC compared with NK cells from healthy
normal donors. NK cells from the patients also had higher
production of immunosuppressive cytokines, TGFβ and IL10
(Jinushi et al., 2004). Thus, as a result of altered NK cells, DCs
from patients with chronic HCV are less likely to drive a strong
adaptive immune response.
Variation in Control Samples Hinders
Interpretation of Hepatic NK Cell Function
during Chronic HCV Infection
Almost all the data discussed in this review relates to peripheral
blood samples from patients with HCV infection. There is only
limited data from liver samples from patients with chronic
HCV. These studies suggest that hepatic NK cell numbers are
either decreased (Kawarabayashi et al., 2000; Boisvert et al.,
2003; Bonorino et al., 2009) or unchanged (Deignan et al.,
2002) in patients with chronic HCV. Hepatic NK cells in
patients with chronic HCV may have lower IFNγ production
(Kawarabayashi et al., 2000) and cytotoxicity/degranulation
capacity (Kawarabayashi et al., 2000; Varchetta et al., 2012)
compared to controls. Furthermore, two studies have shown an
association between high cytotoxicity and reduced liver fibrosis
during chronic HCV (Morishima et al., 2006; Fugier et al., 2014).
However, it should be pointed out that relatively poor cell yields
limit experiments possible while sampling times of liver with
respect to disease (e.g., non-cirrhotic vs. cirrhotic liver) can also
affect results. Furthermore, there is no consistency amongst the
control groups used in the various studies which makes direct
comparisons difficult. Some studies have used “normal” liver
from cancer patients (with cancers other than hepatic cellular
carcinoma, Kawarabayashi et al., 2000) but these are not ideal
as NK cells can be affected in cancer patients and some of the
livers sampled had metastatic disease of the liver (Kawarabayashi
et al., 2000). Other studies compared paired liver and blood
samples but had no healthy liver to provide context for the
liver data (Ahlenstiel et al., 2010, 2011). Yet other studies have
used Non-Alcoholic Fatty Liver Disease (NAFLD) liver biopsy
samples (Fugier et al., 2014), donor liver samples (Deignan et al.,
2002) or liver biopsies taking during non-liver related procedures
(Varchetta et al., 2012) as controls samples. Appropriate control
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groups and adequate sample size of cohorts remain significant
hurdles to this important analysis.
NK Cells in Treatment
The treatment for HCV is rapidly changing with the introduction
of DAAs. However, for many years IFNα and ribavirin was the
standard of care therapy for HCV infection. IFNα is a type 1
IFN that can potently activate NK cells. In light of this, many
studies were performed looking at the effect of IFNα on NK cells
during treatment and correlating these with treatment success or
failure. Given that IFNα is likely to phased out of clinical use
as a front line therapy for HCV and that there is no particular
rationale for DAAs impacting on the NK cell responses other
than to normalize immune functions (Serti et al., 2015), such
treatment studies are unlikely to be a focus on HCV research into
the future.
The Changing Landscape of NK Cell
Biology: Implications for Future HCV
Research
Our knowledge of NK cells is expanding exponentially. Over the
last 15 years, the discovery of complex receptor systems, complex
education processes (Fernandez et al., 2005; Kim et al., 2005;
Anfossi et al., 2006; Joncker et al., 2009; Elliott and Yokoyama,
2011) and “memory” like functions of NK cells have changed the
way we view NK cells. No longer considered simple cells of the
innate immune system, NK cells are now recognized to play roles
beyond what we previously anticipated or expected. All of these
discoveries are likely to impact our understanding of the role that
NK cells play in HCV infection.
There are some relatively newer concepts that may prove
to be particularly important in HCV infection. Firstly, there
is strong evidence emerging that activated NK cells may not
always be beneficial during the immune response to virus.
Data from the LCMV mouse model shows outcome is sensitive
to the relative frequencies of NK cells and T lymphocytes
(Waggoner et al., 2012). In particular, NK cells regulated the
adaptive immune response, by killing CD4+ lymphocytes, and
the system could be manipulated to demonstrate that NK cells
contributed to immune mediated pathology that was lethal for
the animals (Waggoner et al., 2012). Furthermore, NK cells can
potentially impact on the development of immune memory.
In NKp46 deficient mice, an early hyper-responsive NK cell
response was associated with impaired development of specific
memory responses (Narni-Mancinelli et al., 2012). Similarly, NK
cell depletion can lead to higher CD8+ T cells present with
enhanced memory responses (Soderquest et al., 2011). More
recently, data has emerged suggesting that this may also be the
case for human NK cells as they were shown to kill CD8+
T cells during chronic Hepatitis B virus (HBV) infection and
regulate their functions (Peppa et al., 2013). These various data
challenge the paradigm that NK cells are always beneficial in the
anti-viral immune response and serve to illustrate how little we
actually know about how NK cells modulate the development of
specific adaptive immunity. Importantly, they also support the
exciting concept that by modulating NK cell responses during
vaccination, we could promote the development of enhanced
protective immunity to HCV vaccines, a major goal of the HCV
field.
There is also data emerging that supports the presence of
tissue specific NK cells and this may have consequences for organ
specific disease such as HCV infection. The discovery of NK-
like cells (originally termed NK22, now reclassified as ILC3) in
mucosal tissues highlighted the potential role for NK-like cells
in specific organs (Colonna, 2009). While ILC3 have now been
shown to be from a separate lineage, they have many features in
common with NK cells (Artis and Spits, 2015). More compelling
however, is the demonstration of specific tissue resident NK
(trNK) cells that appear to arise from separate lineages (Cortez
et al., 2014; Sojka et al., 2014). Parabiotic mice clearly showed that
NK cells resident in the liver remained there while splenic NK
cells freely circulated between the host and the parabiont (Peng
et al., 2013). Further work has shown that murine liver, uterus
and skin all have particular NK cell subsets characterized by
particular phenotypes, transcriptomes and transcription factors
(Sojka et al., 2014). It is likely therefore that there are distinct
NK cell subsets within the human liver that are not represented
in peripheral blood. The biological significance of this for
hepatic infections such as HCV is not yet clear as we do
not know the function of these tissue resident cells or the
relative importance of resident and circulating conventional NK
(cNK) cells to the HCV specific immune response. However,
information from the murine studies so far suggests that cNK
cells that are found in the liver recirculate into the periphery
and can function as a read out for hepatic immune responses
(Peng et al., 2013). The identification of human counterparts
for these trNK cells is of obvious interest for our understanding
of the role NK cells play in the immune response to HCV.
Finally, the impact of human cytomegalovirus (HCMV) on the
NK cell response to HCV, as has previously been defined for
hantavirus (Björkström et al., 2011), will also be important to
dissect.
In summary, despite all the recent knowledge, it appears that
we only understand a fraction of the role that NK cells play in the
immune response to pathogen. Specifically in HCV, we need to
define what a beneficial NK cell response looks like and if newly
defined NK cell lineages also exist in humans. These need to well
powered with well-defined control populations. In addition to
increasing our basic understanding of how the innate immune
system works, further research may open up the opportunity to
target NK cells as part of a HCV vaccine strategy, an important
research priority within the HCV field.
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